Amgen Inc. (NASDAQ:AMGN) Receives Average Rating of “Hold” from Analysts

Shares of Amgen Inc. (NASDAQ:AMGN) have received a consensus rating of “Hold” from the twenty-one ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $333.7368.

A number of analysts have recently weighed in on AMGN shares. Wells Fargo & Company set a $400.00 price target on Amgen in a research report on Tuesday, November 25th. UBS Group dropped their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Morgan Stanley cut their target price on Amgen from $333.00 to $329.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 5th. DZ Bank boosted their price target on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Saturday.

Amgen Trading Down 2.3%

Amgen stock opened at $337.49 on Thursday. Amgen has a 1 year low of $253.30 and a 1 year high of $345.84. The firm’s 50-day moving average is $308.54 and its 200-day moving average is $295.60. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company has a market cap of $181.73 billion, a P/E ratio of 27.60, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the business earned $5.58 earnings per share. Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts expect that Amgen will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Activity

In other news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.76% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wealth Preservation Advisors LLC acquired a new position in Amgen during the 1st quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the second quarter valued at approximately $27,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares during the period. Evelyn Partners Investment Management LLP bought a new stake in Amgen during the second quarter worth approximately $32,000. Finally, Howard Hughes Medical Institute bought a new stake in Amgen during the second quarter worth approximately $32,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.